Bright Minds Biosciences (DRUG) Change in Receivables (2021 - 2026)

Bright Minds Biosciences (DRUG) has 6 years of Change in Receivables data on file, last reported at $79229.7 in Q1 2026.

• Quarterly Change in Receivables rose 343.19% year-over-year to $79229.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$106493.1 (down 394.82% YoY) and the FY2025 annual result came in at -$147618.1, changed N/A from the prior year.
• Change in Receivables grew to $79229.7 in Q1 2026, from -$42340.4 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $87821.1 in Q2 2022 to a low of -$100427.5 in Q3 2025.
• A 5-year average of -$4650.4 and a median of -$4048.3 in 2024 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2024 — Change in Receivables surged 399.7% — and 2025, when it sank 961.05%.
• Tracing DRUG's Change in Receivables over 5 years: stood at $40697.7 in 2022, then slumped by 85.45% to $5919.6 in 2023, then surged by 399.7% to $29580.3 in 2024, then tumbled by 243.14% to -$42340.4 in 2025, then soared by 287.13% to $79229.7 in 2026.
• The last three Change in Receivables figures came in at $79229.7 (Q1 2026), -$42340.4 (Q4 2025), and -$100427.5 (Q3 2025), per Business Quant data.